# EDGAR Filing Document

**Accession Number:** 0001513525
**File Stem:** 0001213900-25-053828
**Filing Date:** 2025-6
**Character Count:** 2906
**Document Hash:** 3a60642687740a2cb5a5306e0c1f33fd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-053828.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0001213900-25-053828

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADIAL PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001513525
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 800667150
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1180 SEMINOLE TRAIL
- **STREET 2:** SUITE 495
- **CITY:** CHARLOTTESVILLE
- **STATE:** VA
- **ZIP:** 22901
- **BUSINESS PHONE:** 434-422-9800

**MAIL ADDRESS:**
- **STREET 1:** 1180 SEMINOLE TRAIL
- **STREET 2:** SUITE 495
- **CITY:** CHARLOTTESVILLE
- **STATE:** VA
- **ZIP:** 22901

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADial Pharmaceuticals, L.L.C.
- **DATE OF NAME CHANGE:** 20170515

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adial Pharmaceuticals, L.L.C.
- **DATE OF NAME CHANGE:** 20110218

![](image_001.jpg)

June 12, 2025

 ****

***<u>VIA EDGAR</u>***

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Doris Stacy Gama

---

| | |
|:---|:---|
| **Re:** | **Adial Pharmaceuticals, Inc.** |
|  | **Registration Statement on Form S-1** |
|  | **Filed June 6, 2025**<br> **File No: 333-287826** |

---

Dear Ms. Gama:

Adial Pharmaceuticals, Inc. (the "**Registrant**") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-287826), be accelerated by the U.S. Securities and Exchange Commission (the "**Commission**") to become effective on **Monday, June 16, 2025**, at **9:15 a.m**., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| ADIAL PHARMACEUITCALS, INC. | ADIAL PHARMACEUITCALS, INC. | ADIAL PHARMACEUITCALS, INC. |
| By: | /s/ Cary Claiborne | /s/ Cary Claiborne |
|  | Name: | Cary Claiborne |
|  | Title: | Chief Executive Officer |

---

cc: Leslie Marlow, Blank Rome LLP